De novo small deletion affecting transcription start site of short isoform of AUTS2 gene in a patient with syndromic neurodevelopmental defects.


Journal

American journal of medical genetics. Part A
ISSN: 1552-4833
Titre abrégé: Am J Med Genet A
Pays: United States
ID NLM: 101235741

Informations de publication

Date de publication:
03 2021
Historique:
received: 05 08 2020
revised: 03 11 2020
accepted: 22 11 2020
pubmed: 22 12 2020
medline: 20 7 2021
entrez: 21 12 2020
Statut: ppublish

Résumé

Disruption of the autism susceptibility candidate 2 (AUTS2) gene through genomic rearrangements, copy number variations (CNVs), and intragenic deletions and mutations, has been recurrently involved in syndromic forms of developmental delay and intellectual disability, known as AUTS2 syndrome. The AUTS2 gene plays an important role in regulation of neuronal migration, and when altered, associates with a variable phenotype from severely to mildly affected patients. The more severe phenotypes significantly correlate with the presence of defects affecting the C-terminus part of the gene. This article reports a new patient with a syndromic neurodevelopmental disorder, who presents a deletion of 30 nucleotides in the exon 9 of the AUTS2 gene. Importantly, this deletion includes the transcription start site for the AUTS2 short transcript isoform, which has an important role in brain development. Gene expression analysis of AUTS2 full-length and short isoforms revealed that the deletion found in this patient causes a remarkable reduction in the expression level, not only of the short isoform, but also of the full AUTS2 transcripts. This report adds more evidence for the role of mutated AUTS2 short transcripts in the development of a severe phenotype in the AUTS2 syndrome.

Identifiants

pubmed: 33346930
doi: 10.1002/ajmg.a.62017
doi:

Substances chimiques

AUTS2 protein, human 0
Cytoskeletal Proteins 0
Protein Isoforms 0
RNA, Messenger 0
Transcription Factors 0

Types de publication

Case Reports

Langues

eng

Sous-ensembles de citation

IM

Pagination

877-883

Informations de copyright

© 2020 Wiley Periodicals LLC.

Références

Amarillo, I. E., Li, W. L., Li, X., Vilain, E., & Kantarci, S. (2014). De novo single exon deletion of AUTS2 in a patient with speech and language disorder: A review of disrupted AUTS2 and further evidence for its role in neurodevelopmental disorders. American Journal of Medical Genetics-Part A, 164, 958-965.
Beunders, G., de Munnik, S. A., Van der Aa, N., Ceulemans, B., Voorhoeve, E., Groffen, A. J., … Sistermans, E. A. (2015). Two male adults with pathogenic AUTS2 variants, including a two-base pair deletion, further delineate the AUTS2 syndrome. The European Journal of Human Genetics, 23, 803-807.
Beunders, G., van de Kamp, J., Vasudevan, P., Morton, J., Smets, K., Kleefstra, T., … Sistermans, E. A. (2016). A detailed clinical analysis of 13 patients with AUTS2 syndrome further delineates the phenotypic spectrum and underscores the behavioural phenotype. The Journal of Medical Genetics, 53, 523-532.
Beunders, G., Voorhoeve, E., Golzio, C., Pardo, L. M., Rosenfeld, J. A., Talkowski, M. E., … Sistermans, E. A. (2013). Exonic deletions in AUTS2 cause a syndromic form of intellectual disability and suggest a critical role for the C terminus. American Journal of Human Genetics, 92, 210-220.
Fan, Y., Qiu, W., Wang, L., Gu, X., & Yu, Y. (2016). Exonic deletions of AUTS2 in Chinese patients with developmental delay and intellectual disability. The American Journal of Medical Genetics-Part A, 170, 515-522.
Gao, Z., Lee, P., Stafford, J. M., Von, S. M., Schaefer, A., & Reinberg, D. (2014). An AUTS2-Polycomb complex activates gene expression in the CNS. Nature, 516, 349-354.
Hori, K., & Hoshino, M. (2017). Neuronal migration and AUTS2 syndrome. Brain Sciences, 7, 54.
Hori, K., Nagai, T., Shan, W., Sakamoto, A., Taya, S., Hashimoto, R., … Hoshino, M. (2014). Cytoskeletal regulation by AUTS2 in neuronal migration and neuritogenesis. Cell Reports, 9, 2166-2179.
Huang, X. L., Zou, Y. S., Maher, T. A., Newton, S., & Milunsky, J. M. (2010). A de novo balanced translocation breakpoint truncating the autism susceptibility candidate 2 (AUTS2) gene in a patient with autism. The American Journal of Medical Genetics-Part A, 152, 2112-2114.
Jolley, A., Corbett, M., McGregor, L., Waters, W., Brown, S., Nicholl, J., & Yu, S. (2013). De novo intragenic deletion of the autism susceptibility candidate 2 (AUTS2) gene in a patient with developmental delay: A case report and literature review. The American Journal of Medical Genetics-Part A, 161, 1508-1512.
Kalscheuer, V. M., FitzPatrick, D., Tommerup, N., Bugge, M., Niebuhr, E., Neumann, L. M., … Ullmann, R. (2007). Mutations in autism susceptibility candidate 2 (AUTS2) in patients with mental retardation. Human Genetics, 121, 501-509.
Li, M. X., Gui, H. S., Kwan, J. S., Bao, S. Y., & Sham, P. C. (2012). A comprehensive framework for prioritizing variants in exome sequencing studies of Mendelian diseases. Nucleic Acids Research, 40, e53.
Liu, Y., Zhao, D., Dong, R., Yang, X., Zhang, Y., Tammimies, K., … Gai, Z. (2015). De novo exon 1 deletion of AUTS2 gene in a patient with autism spectrum disorder and developmental delay: A case report and a brief literature review. The American Journal of Medical Genetics-Part A, 167, 1381-1385.
Lopez-Martin, E., Martinez-Delgado, B., Bermejo-Sanchez, E., Alonso, J., & Posada, M. (2018). SpainUDP: The Spanish undiagnosed rare diseases program. The International Journal of Environmental Research and Public Health, 15, 1746.
McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky, A., … DePristo, M. A. (2010). The genome analysis toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data. Genome Research, 20, 1297-1303.
Monderer-Rothkoff, G., Tal, N., Risman, M., Shani, O., Nissim-Rafinia, M., Malki-Feldman, L., … Shifman, S. (2019). AUTS2 isoforms control neuronal differentiation. Molecular Psychiatry. https://doi.org/10.1038/s41380-019-0409-1.
Nagamani, S. C., Erez, A., Ben-Zeev, B., Frydman, M., Winter, S., Zeller, R., … Cheung, S. W. (2013). Detection of copy-number variation in AUTS2 gene by targeted exonic array CGH in patients with developmental delay and autistic spectrum disorders. The European Journal of Human Genetics, 21, 343-346.
Oksenberg, N., Haliburton, G. D., Eckalbar, W. L., Oren, I., Nishizaki, S., Murphy, K., … Ahituv, N. (2014). Genome-wide distribution of Auts2 binding localizes with active neurodevelopmental genes. Translational Psychiatry, 4, e431.
Pizzo, L., Jensen, M., Polyak, A., Rosenfeld, J. A., Mannik, K., Krishnan, A., … Girirajan, S. (2019). Rare variants in the genetic background modulate cognitive and developmental phenotypes in individuals carrying disease-associated variants. Genetics in Medicine, 21, 816-825.
Saeki, S., Enokizono, T., Imagawa, K., Fukushima, H., Kajikawa, D., Sakai, A., … Takada, H. (2019). A case of autism spectrum disorder with cleft lip and palate carrying a mutation in exon 8 of AUTS2. Clinical Case Reports, 7, 2059-2063.
Sengun, E., Yararbas, K., Kasakyan, S., & Alanay, Y. (2016). AUTS2 syndrome in a 68-year-old female: Natural history and further delineation of the phenotype. The American Journal of Medical Genetics-Part A, 170, 3231-3236.
Sultana, R., Yu, C. E., Yu, J., Munson, J., Chen, D., Hua, W., … Villacres, E. C. (2002). Identification of a novel gene on chromosome 7q11.2 interrupted by a translocation breakpoint in a pair of autistic twins. Genomics, 80, 129-134.

Auteurs

Beatriz Martinez-Delgado (B)

Institute of Rare Diseases Research (Instituto de Investigación de Enfermedades Raras/IIER), Carlos III Institute of Health (Instituto de Salud Carlos III/ISCIII), Madrid, Spain.
Consortium for Biomedical Research in Rare Diseases (CIBER de Enfermedades Raras/CIBERER) (CB06/07/1009), ISCIII, Madrid, Spain.
Undiagnosed Diseases Network International, Madrid, Spain.

Estrella Lopez-Martin (E)

Institute of Rare Diseases Research (Instituto de Investigación de Enfermedades Raras/IIER), Carlos III Institute of Health (Instituto de Salud Carlos III/ISCIII), Madrid, Spain.
Consortium for Biomedical Research in Rare Diseases (CIBER de Enfermedades Raras/CIBERER) (CB06/07/1009), ISCIII, Madrid, Spain.
Undiagnosed Diseases Network International, Madrid, Spain.

Julián Lara-Herguedas (J)

Department of Neuropediatrics, Puerta de Hierro University Teaching Hospital, Madrid, Spain.

Sara Monzon (S)

Undiagnosed Diseases Network International, Madrid, Spain.
Bioinformatics Unit, ISCIII, Madrid, Spain.

Isabel Cuesta (I)

Undiagnosed Diseases Network International, Madrid, Spain.
Bioinformatics Unit, ISCIII, Madrid, Spain.

Miguel Juliá (M)

Undiagnosed Diseases Network International, Madrid, Spain.
Bioinformatics Unit, ISCIII, Madrid, Spain.

Virginia Aquino (V)

Institute of Rare Diseases Research (Instituto de Investigación de Enfermedades Raras/IIER), Carlos III Institute of Health (Instituto de Salud Carlos III/ISCIII), Madrid, Spain.

Carlos Rodriguez-Martin (C)

Institute of Rare Diseases Research (Instituto de Investigación de Enfermedades Raras/IIER), Carlos III Institute of Health (Instituto de Salud Carlos III/ISCIII), Madrid, Spain.

Alejandra Damian (A)

Institute of Rare Diseases Research (Instituto de Investigación de Enfermedades Raras/IIER), Carlos III Institute of Health (Instituto de Salud Carlos III/ISCIII), Madrid, Spain.

Irene Gonzalo (I)

Institute of Rare Diseases Research (Instituto de Investigación de Enfermedades Raras/IIER), Carlos III Institute of Health (Instituto de Salud Carlos III/ISCIII), Madrid, Spain.

Gema Gomez-Mariano (G)

Institute of Rare Diseases Research (Instituto de Investigación de Enfermedades Raras/IIER), Carlos III Institute of Health (Instituto de Salud Carlos III/ISCIII), Madrid, Spain.
Undiagnosed Diseases Network International, Madrid, Spain.

Beatriz Baladron (B)

Institute of Rare Diseases Research (Instituto de Investigación de Enfermedades Raras/IIER), Carlos III Institute of Health (Instituto de Salud Carlos III/ISCIII), Madrid, Spain.
Undiagnosed Diseases Network International, Madrid, Spain.

Rosario Cazorla (R)

Department of Neuropediatrics, Puerta de Hierro University Teaching Hospital, Madrid, Spain.

Gema Iglesias (G)

Department of Neuropediatrics, Puerta de Hierro University Teaching Hospital, Madrid, Spain.

Enriqueta Roman (E)

Department of Neuropediatrics, Puerta de Hierro University Teaching Hospital, Madrid, Spain.

Purificacion Ros (P)

Undiagnosed Diseases Network International, Madrid, Spain.

Pablo Tutor (P)

Department of Internal Medicine, Puerta de Hierro University Teaching Hospital, Madrid, Spain.

Susana Mellor (S)

Department of Internal Medicine, Puerta de Hierro University Teaching Hospital, Madrid, Spain.

Carlos Jimenez (C)

Department of Neurology, Puerta de Hierro University Teaching Hospital, Madrid, Spain.

Maria Jose Cabrejas (MJ)

Department of Clinical Biochemistry, Puerta de Hierro University Teaching Hospital, Madrid, Spain.

Emiliano Gonzalez-Vioque (E)

Department of Clinical Biochemistry, Puerta de Hierro University Teaching Hospital, Madrid, Spain.

Javier Alonso (J)

Institute of Rare Diseases Research (Instituto de Investigación de Enfermedades Raras/IIER), Carlos III Institute of Health (Instituto de Salud Carlos III/ISCIII), Madrid, Spain.
Consortium for Biomedical Research in Rare Diseases (CIBER de Enfermedades Raras/CIBERER) (CB06/07/1009), ISCIII, Madrid, Spain.
Undiagnosed Diseases Network International, Madrid, Spain.

Eva Bermejo-Sánchez (E)

Institute of Rare Diseases Research (Instituto de Investigación de Enfermedades Raras/IIER), Carlos III Institute of Health (Instituto de Salud Carlos III/ISCIII), Madrid, Spain.
Undiagnosed Diseases Network International, Madrid, Spain.

Manuel Posada (M)

Institute of Rare Diseases Research (Instituto de Investigación de Enfermedades Raras/IIER), Carlos III Institute of Health (Instituto de Salud Carlos III/ISCIII), Madrid, Spain.
Consortium for Biomedical Research in Rare Diseases (CIBER de Enfermedades Raras/CIBERER) (CB06/07/1009), ISCIII, Madrid, Spain.
Undiagnosed Diseases Network International, Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH